

# Reproducible therapeutic effects of lanifibranor and elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

## Authors

Michael Feigh, Denise Oró, Dagne Barbuskaite, Nicolas Eskesen, Henrik H. Hansen

Gubra, Hørsholm, Denmark

## Corresponding author

Michael Feigh - mfe@gubra.dk


## Background & Aim

Various peroxisome proliferator-activated receptor (PPAR) agonists, including lanifibranor (PPAR- $\alpha/\delta/\gamma$  agonist), elafibranor (PPAR- $\alpha/\delta$  agonist) and seladelpar (PPAR- $\delta$  agonist), have been profiled in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to evaluate robustness of therapeutic outcomes following treatment with these clinically relevant PPAR agonists in the translational GAN diet-induced obese (DIO) mouse model of biopsy-confirmed MASH and fibrosis.


## Methods

Lanifibranor (study 1-2), elafibranor (study 3-5) and seladelpar (study 6) monotherapy was profiled in GAN DIO-MASH mice. C57BL/6J mice were fed the GAN diet high in saturated fat, fructose, and cholesterol for 33-44 weeks before treatment start. Only animals with biopsy-confirmed MASH (NAS $\geq$ 5) and fibrosis (stage  $\geq$ F1) were included and stratified into treatment groups. GAN DIO-MASH mice (n=14-18 per group) received (PO) lanifibranor (Lani, 30 mg/kg), elafibranor (Ela, 30 mg/kg), seladelpar (14.1 mg/kg) or vehicle (Veh) once daily for 12 weeks. Vehicle-dosed chow-fed controls served as healthy controls (Lean). Within-subject comparisons (pre- vs. post-treatment) were performed for NAS and fibrosis stage. Terminal quantitative endpoints included plasma/liver biochemistry and AI-based quantitative liver histology. Statistical analyses were performed using Dunnett's test one-factor linear model (individual studies), Fisher's exact test (pooled study data on semiquantitative histopathological scoring variables) or one-way ANOVA with Dunnett's post-hoc test (pooled study data on quantitative endpoints), respectively. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 compared to corresponding vehicle controls.


## 1 Study outline




## 2 Body weight




## 3 Liver weight & transaminases






## 4 Plasma total cholesterol & triglycerides



## 5 NAFLD Activity Score (NAS) & Fibrosis stage



## 6 Quantitative histological markers of steatosis, inflammation & fibrosis



## Conclusion

- + Three clinically relevant PPAR agonists were profiled in GAN DIO-MASH mice
- + All compounds reduces body weight and improves transaminases and hypercholesterolemia. Elafibranor and seladelpar increases liver weight
- + Lanifibranor and elafibranor reproducibly improves MASH by reducing steatosis and lobular inflammation scores. Seladelpar shows a comparable efficacy profile
- + Inconsistent (lanifibranor) or no (elafibranor, seladelpar) effects on fibrosis scores were observed
- + Benefits on histopathological scores were supported by quantitative histology



Scan the QR code to see the poster online

[www.gubra.dk](http://www.gubra.dk)